Table 2

Baseline demographic, clinical and radiographic characteristics of the patients included in assessment of the radiographic progression in this study.

Assessment

N = 195*

Age (years)

42.8 (12.4)

Male gender (%)

138 (71%)

HLA-B27 positive (%)

158 (84%)

Symptoms duration (years)

20.4 (12.9)

Disease duration (years)

11.0 (8.7)

ASDAS-CRP

2.7 (1.0)

BASDAI (0-10)

3.4 (2.0)

BASFI (0-10)

3.2 (2.5)

BASMI (0-10)

3.7 (1.5)

CRP (mg/l) (N = 186)

17.5 (23.5)

Elevated CRP (%)‡

96 (52%)

mSASSS (0-72) (N = 177)¥

10.8 (15.2)

RASSS (0-84) (N = 130)

11.8 (16.6)

mSASSS of patients with available RASSS (0-72) (N = 130)

10.1 (14.2)

mSASSS > 0 (%) (N = 177)

143 (81%)

RASSS > 0 (%) (N = 130)

107 (82%)

mSASSS > 0 of patients with available RASSS (%) (N = 130)

106 (82%)

*Data are presented as mean (SD) or n (%). N = 195, representing patients with ≥ 1 radiograph with the mSASSS evaluable throughout follow-up (not necessarily at baseline available). ‡The cutoff was 10 mg/l for the Dutch patients (n = 122) and 5 mg/l for the Belgian (n = 23) and French patients (n = 50); ¥18 patients did not have a radiograph with an mSASSS evaluable at baseline, but had a radiograph in which the mSASSS could be calculated at a later time point and were therefore included in the study. ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score (C-reactive protein); BASDAI, Bath Ankylosing Spondylitis Disease Activity Score; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; RASSS, radiographic Ankylosing Spondylitis Spinal Score.

Ramiro et al. Arthritis Research & Therapy 2013 15:R14   doi:10.1186/ar4144